Kornimate/medical-research-clean huggingface dataset:
fracture pattern following bilateral sagittal split osteotomy with or without impacted third molars

Conditions: Impacted Third Molar Tooth; Osteotomy; Orthognathic Surgery; Mandibular Fractures

Summary: the goal of this clinical trial is to investigate the hypothesis that there are none difference in the treatment result of orthognathic surgery on the lower jaw, with interoperative wisdom tooth removal rather than preoperative wisdom tooth removal. in patients with severe dental malocclusion combined with a dentofacial deformity. the main question it aims to answer are: • is there a difference in the degree of complication and the patient's perception, with inter-operative wisdom tooth removal rather than pre-operative wisdom tooth removal. participants will be will be divided into two groups, with one group having their wisdom teeth removed 6 months before their jaw moving surgery and the other group having their wisdom teeth removed in connection with their jaw moving surgery.


Eligibility criteria:
inclusion criteria: * patients scheduled for surgical correction of facial deformities involving bsso or bimaxillary surgery with bilateral asymptomatic impacted mandibular third molars * age between 18 and 75 years exclusion criteria: * fully erupted and well-functioning mandibular third molar * unilateral impacted mandibular third molar * pathology associated with the impacted mandibular third molar * bsso combined with genioplasty * previous mandibular fractures * present neurosensory disturbances of the inferior alveolar nerve * systemic bone disease or arthritis * physical status classification system, asa class iii or iv, specified patients with severe systemic disease ore patients with severe systemic disease that is constant threat to life * failure to attend the entire observation period
emergency stroke unit for acute cerebrovascular events ( esu-ace-d )

Conditions: Ischemic Stroke, Acute

Summary: to compare the prognosis of patients with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) managed in a standard stroke unit adherent to guidelines versus managed in emergency stroke unit (a new stroke unit based on low-field magnetic resonance imaging).

the first mri machines in the 1970s and 1980s were low-field due to technological limitations. as technology advanced, the focus shifted to higher field strengths to achieve better image resolution and faster scan times. recently, there has been renewed interest in low-field mri due to advancements in hardware and software, making them more viable for specific clinical applications, including acute stroke. prompt and accurate imaging is crucial for diagnosing ischemic stroke and determining the appropriate treatment (e.g., thrombolysis or thrombectomy). research has demonstrated that low-field mri can effectively detect acute ischemic changes and distinguish between ischemic and hemorrhagic stroke. by providing accessible, cost-effective, and safe imaging, it can facilitate timely and accurate treatment, particularly in settings where high-field mri is not readily available. this prospective, multicenter, week-wise randomized controlled trial will compare the prognosis of patients with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) managed in a standard stroke unit adherent to guidelines versus managed in emergency stroke unit (a new stroke unit based on low-field magnetic resonance imaging).

Eligibility criteria:
1. age ≥ 18 years; 2. patients who arrive at the emergency department between 4.5-6 hours of symptom onset\* (\*symptom onset is defined by the "last seen normal" principle); 3. presenting with ischemic stroke symptoms; 4. pre-stroke mrs score 0-1; 5. baseline nihss score ≥ 5; 6. eligible for endovascular thrombectomy; 7. informed consent signed. exclusion criteria: 1. baseline nihss score \< 5; 2. unable to undergo mri because of claustrophobia; 3. patients with cardiac pacemaker/brain pacemaker/insulin pump implantation; 4. definite contraindication for endovascular thrombectomy; 5. patients with postictal hemiparesis (todd's paralysis) or those with concomitant neurological/psychiatric conditions who are unable or unwilling to cooperate; 6. pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial; 7. participation in other interventional randomized clinical trials within 3 months before enrollment; 8. patients deemed unsuitable for participation in this trial by the investigator or those for whom participation in this trial may result in greater risks.

Keywords: emergency stroke unit low-field magnetic resonance imaging reperfusion therapy
a study of dc-cik to treat hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma (HCC)

Summary: the purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (dc-cik) for hepatocellular carcinoma (hcc).

about 60 patients with hcc, who had received complete resection or tace and got complete remission (cr) or partial response (pr), will be randomly divided into group a (receive dc-cik treatment) or group b (just regularly follow up), and the randomize ratio will be 1:1. patients in group a will receive 2-3 cycles of dc-cik cells treatment (every 4 weeks). patients in group b will have no anti-tumor therapy.

Eligibility criteria:
inclusion criteria: 1. male or female patients \> 18 years of age; 2. hepatocellular carcinoma with histological or imaging and afp diagnose, and had received complete resection or tace and got cr or pr by imaging studies; 3. patients who have a life expectancy of at least 12 weeks; 4. eastern cooperative oncology group (ecog) performance status was 0 - 1; 5. the bone marrow functioned normally (wbc \> 4.0×109/l, hb \> 120 g/l, plt \> 100×109/l); 6. the ecg results were normal, and the liver and kidney were functional. exclusion criteria: 1. patients who had distant metastases; 2. patients with uncontrolled infection; underlying disease that was severe or life-threatening; 3. patients who were pregnant or lactating; 4. ecog perform status ≥ 2; 5. patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.

Keywords: hepatocellular carcinoma, dc-cik
physical functional side effects of taxane chemotherapy for breast cancer

Conditions: Breast Cancer

Summary: determine the characteristics of symptoms and functional impairment associated with chemotherapy induced peripheral neuropathy.

taxanes, a type of chemotherapeutic agent prescribed to breast cancer patients, have a known physical side effect of chemotherapy induced peripheral neuropathy (cipn). the purpose of this qualitative study is to understand the experience and physical functional side effects of taxanes. this is the first of a two phase study. the overall goal is to identify existing objective physical performance measures to assess functional side effects of taxanes.

Eligibility criteria:
inclusion criteria: * women 21-70 years old (women over 70 are offered chemotherapy less frequently because of their risk benefit ratio. including them would be a selection bias because of their differential underexposure). * initiated taxane-based chemotherapy in the neoadjuvant, adjuvant, or previously untreated metastatic setting. * the range of exposure to taxane-based chemotherapy will include women on active treatment having received two cycles, to women who are within three months of their last infusion. * documented symptoms of cipn per ctcae grading criteria (half of sample) or no symptoms (half of sample) grade 0 = no cipn symptoms grade 1 = mild symptoms grade 2 = moderate symptoms - prescribed gabapentin (neurontin) grade 3\&4= severe symptoms - treated with gabapentin (neurontin), treatment plan altered exclusion criteria: * physical disabilities - defined by use of assistive devices to complete functional tasks (wheelchair, crutches, prosthetic limbs) prior to starting chemotherapy. * current exposure to neurotoxic agents (navelbine, platinums or other taxanes) * pregnancy during chemotherapy treatment * diabetes - diagnosed 3 or more years , or insulin dependent, or with clinically established neuropathy * previous exposure to chemotherapy or radiotherapy * hiv positive (high risk for neuropathy) * other neurological diseases, such as multiple sclerosis * other pre-existing neuropathy

Keywords: breast cancer patients
a phase 2 open-label study of the efficacy and safety of abt-199 (gdc-0199) in chronic lymphocytic leukemia (cll) subjects with relapse or refractory to b-cell receptor signaling pathway inhibitor therapy

Conditions: Chronic Lymphocytic Leukemia

Summary: this was an open-label, non-randomized, multicenter, phase 2 study evaluating the efficacy and safety of abt-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (cll) after b-cell receptor signaling pathway inhibitors (bcr pi) treatment.


Eligibility criteria:
inclusion criteria: * participant must have a diagnosis of chronic lymphocytic leukemia (cll) that meets 2008 modified international workshop on chronic lymphocytic leukemia national cancer institute-working group (iwcll nci-wg) criteria * participant has relapsed/refractory disease with an indication for treatment * participant has refractory disease or developed recurrence after therapy with a b-cell receptor pathway inhibitor (bcr pi) * participant must have an eastern cooperative oncology group performance score of ≤ 2 * participant must have adequate bone marrow function at screening * participant must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at screening exclusion criteria: * participant has undergone an allogeneic stem cell transplant within the past year * participant has developed richter's transformation confirmed by biopsy * participant has active and uncontrolled autoimmune cytopenia * participant has malabsorption syndrome or other condition that precludes enteral route of administration * participant is human immunodeficiency virus (hiv) positive or has chronic hepatitis b or hepatitis c virus requiring treatment * participant has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase

Keywords: oncology chronic lymphocytic leukemia cancer of the blood and bone marrow
bladder cancer longitudinal biorepository for development of novel therapeutics/biomarkers

Conditions: Bladder Cancer

Summary: the purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. the registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.


Eligibility criteria:
inclusion criteria: * patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate * patients can participate in any additional research studies during the patients' participation within this protocol. exclusion criteria: * patients who do not have presumed bladder cancer will not be eligible
effect of snags and scapular mobilizations in patients with scapulocostal syndrome

Conditions: Scapulocostal Syndrome

Summary: to determine the impact of snags and scapular mobilizations on pain, cervical and shoulder range of motion and functional outcomes in individuals with scapulocostal syndrome.

the rationale for employing snags (sustained natural apophyseal glides) in treating scapulocostal syndrome is multifaceted. by targeting specific joint surfaces and soft tissue structures, snags aim to address joint dysfunction, alleviate pain, and improve mobility in the scapulothoracic region. these sustained gliding movements not only modulate pain signals but also promote relaxation and reduce muscle tension, thereby enhancing the effectiveness of therapeutic exercises aimed at strengthening the surrounding musculature. additionally, snags facilitate proper muscle activation patterns, optimizing muscle function and coordination. their adaptability allows for a patient-centered approach, ensuring tailored treatment that considers individual symptoms, mobility deficits, and treatment goals, ultimately promoting better functional outcomes in individuals with scapulocostal syndrome.

Eligibility criteria:
inclusion criteria: * age- 18 to 40 years. * male and female both * nonspecific neck pain with a duration of greater than 3 months * no pain reproduction on isometric muscle testing in shoulder. * patients who could not achieve 60 degrees of upward rotation when elevating the arms above the head i.e. presence of scapular dyskinesia * pain with a referral pattern while receiving manual pressure of at least 3 points on the medial scapular muscles (levator scapulae, rhomboid major, rhomboid minor, and serratus posterior superior) evaluated through travels and simon criteria. * discomfort, pain, or limitations in neck extension, neck rotation bilaterally, shoulder forward flexion, shoulder abduction attributed to scs. * willing to provide informed consent to participate in the study. exclusion criteria: * musculoskeletal pathologies affecting the cervical spine or lower extremities (e.g., herniated disc, cervical radiculopathy, cervical stenosis, shoulder labral tear). * history of degenerative shoulder joint disease * rotator cuff dysfunction * thoracic outlet syndrome * brachial neuralgia * shoulder impingement syndrome * adhesive capsulitis * pregnant individuals due to potential discomfort. * open wounds, infections, or skin conditions at pain site.

Keywords: non specific neck pain snags scapular mobilizations ndi
a double-blind randomized clinical trial comparing the safety and antiviral activity of 48-week clevudine and adefovir dipivoxil in hbeag(-) chronic hepatitis b with compensated liver function

Conditions: HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Summary: a double-blind randomized, parallel, multicenter with 48 weeks of treatment period. the purpose of this study is to compare the safety and antiviral activity of 48-week clevudine and adefovir dipivoxil in hbeag(-) chronic hepatitis b with compensated liver function.


Eligibility criteria:
inclusion criteria: * patient is between 18 and 60 * patient is documented to be hbsag positive for \> 6 months. * patient with compensated hepatic function. * nucleoside treatment-naã-ve subjects of either gender * patient is hbeag negative. patient is hbv dna positive with dna levels â‰¥ 1 x 10(5) copies/ml within 30 days of baseline. * patient has alt levels which are in the range of 2 x uln and \< 10 x uln * patient who has not a history of ascites, variceal hemorrhage or hepatic encephalopathy. exclusion criteria * patient is currently receiving antiviral or corticosteroid therapy. * patients previously treated with lamivudine, adefovir, entecavir, telbivudine, clevudine, lobucavir, famciclovir or any other investigational nucleoside for hbv infection. * previous treatment with interferon must have ended at least 6 months prior to the screening visit. * treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic drugs within 2 months before study screening or during the study period * subjects who are currently participating in another investigational study or has been taking any investigational drug within the last 4 weeks prior to screening visit. * patient is coinfected with hcv, hdv or hiv. * patient with following clinical evidence * decompensated liver cirrhosis (child class b,c: cpt score 7) or hepatocellular carcinoma * significant gastrointestinal, renal, bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease * previous organ transplantation * patient has a clinically relevant history of abuse of alcohol or drugs. * patient is pregnant or breast-feeding. * patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. * patient has î±-fetoprotein more than 100ng/ml * patient has hemoglobin \<11g/dl (male), 10g/dl (female) or wbc count \< 3,500/mm3 (pmn\<1,500/mm3) or platelet count \<50,000/mm3 * patient has creatinine clearance less than 60ml/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dl\]) \[note: multiply estimates by 0.85 for women\]
study of the expression of circulating and intra-tumoral chemokines in patients with prostate cancer

Conditions: Prostate Cancer

Summary: multicentric, observational, prospective, non-interventional study with occasional biological sample collection (serum bank, urine bank and tumor bank)

this project is an exploratory study, based on the hypothesis of involvement of chemokines in hormonal escape of prostate cancers. the two main objectives are: * to describe the variations in expression of chemokines in serum and urine level in patients with prostate cancer * and to study the disease stage and intra-prostatic concentrations of chemokines based on serum and urine concentrations of chemokines before treatment initiation. these estimates can be used in future trials set up for the management of prostate cancer

Eligibility criteria:
inclusion criteria: * patients with a localized or metastatic prostate adenocarcinoma for which a new treatment will be implemented (hormone therapy for single biological relapse or relapses and metastatic hormone-sensitive) or chemotherapy (for biological relapses and / or metastatic hormone-resistant) * patients with a detectable psa (prostate-specific antigen) * patients who signed an informed consent * patients over 18 years * patients belonging to the social security scheme exclusion criteria: * active hepatitis b or c virus * hiv positive * patients who have received prior chemotherapy * patients with a second neoplasia treated in the last 5 years
study of the safety and efficacy of conversion from a cni to sirolimus in renally-impaired heart transplant recipients

Conditions: Graft Rejection; Kidney Failure

Summary: the primary purpose of this study is to determine whether converting from calcineurin inhibitor (cni) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal dysfunction.


Eligibility criteria:
inclusion criteria: * cardiac transplant recipients age 18 years or older receiving cyclosporine or tacrolimus since the time of transplant. * 12 months after cardiac transplantation but less than 96 months post-transplantation. exclusion criteria: * multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart after kidney transplant recipients). * prior or current use of sirolimus or everolimus unless administration was part of a "cni holiday" lasting no more than 10 days. * history of acute rejection within the last 3 months, malignancy within the last 5 years (except for adequately treated basal cell or squamous cell carcinoma of the skin), and human immunodeficiency virus (hiv) patients.

Keywords: heart transplant kidney failure
therapeutic merit of solifenacin in the mitigation of ureteral stent-induced pain and lower urinary tract symptoms

Conditions: Flank Pain; Urinary Bladder, Overactive

Summary: most ureteral stent insertions follow ureteroscopy procedures for stone management. stents are essentially designed to prevent the blockage of the ureter. such blockage is often a result of inflammation caused by ureteroscopy procedures. the stent provides a secure passageway for urine as it travels from the kidneys to the bladder, circumventing potential urinary retention. in our community, only one kind of stent is used, and it is manufactured by bard. standard protocol involves the removal of the stent 5 to 8 days following insertion. if stenting is required for greater than 8 days, special accommodations will be made for you in this study. unfortunately, pain and lower urinary tract symptoms are often associated with the insertion and removal of stents. it is our goal to determine whether vesicare is capable of relieving such symptoms. as a prospective member of this study, you will be asked to complete three surveys. the first survey will ask you about your experiences of urinary urgency and pain before your surgery. if you are an emergency patient, you will be asked to remember your condition before the surgery, completing this questionnaire at your first post-op visit. if you are not an emergency patient, this survey will be completed before your surgery. if your stent is removed within 5 to 8 days of surgery, you will be asked to complete the second survey at the time of removal. you will then complete the final survey at a scheduled post-operative check-up 4 to 5 weeks later. if your stent remains inserted for greater than 8 days after surgery, you will be asked to complete the second survey 3 to 4 days after your stent was inserted. you will then complete the final survey, 7 to 8 weeks post-op. throughout this study, both vesicare and non-vesicare patients will be important in determining whether vesicare truly is capable of relieving stent pain. as such, you will be randomly assigned to one of the two groups, those receiving vesicare, and those who are not.


Eligibility criteria:
subject inclusion criteria. 1. post-ureteroscopy for stone management. 2. stent inserted for more than 5 days. 3. no significant flank pain or luts prior to kidney stones/stent insertion. 4. complete agreement with and signing of informed consent form. subject exclusion criteria. 1. significant flank pain or luts prior to kidney stones/stent insertion. 2. currently taking antimuscarinics or α1 blockers. 3. patients with urinary retention, dependent on dialysis, gastroparesis or narrow angle glaucoma.

Keywords: flank pain lower urinary tract symptoms luts urgency nocturia frequency ureteroscopy kidney stones stent incontinence vesicare ureter urinary bladder, overactive oab overactive bladder syndrome